🔗 Share this article

Chancellor Rachel Reeves has announced she is planning "focused measures to deal with cost of living pressures" in next month's Budget.

During an interview with media outlets, she noted that curbing price rises is a collective responsibility of both the administration and the central bank.

The UK's inflation rate is forecast to be the most elevated among the G7 industrialized countries this calendar year and the following year.

Potential Energy Bill Measures

Sources suggest the government could intervene to lower utility costs, for instance by cutting the present 5% level of value-added tax charged on energy.

Another approach is to lower some of the government charges presently added to bills.

Budgetary Constraints and Expert Predictions

The administration will obtain the next draft from the independent fiscal watchdog, the Office for Budget Responsibility, on Monday, which will reveal how much space there is for such measures.

The view from the majority of analysts is that Reeves will have to declare tax rises or spending cuts in order to fulfill her declared borrowing rules.

Previously on Thursday, estimates indicated there was a £22bn gap for the Treasury chief to address, which is at the more modest range of forecasts.

"There's a shared job between the central bank and the government to further reduce some of the causes of price increases," Reeves told the BBC in the US capital, at the conferences of the International Monetary Fund and global financial institution.

Revenue Commitments and Global Issues

While a great deal of the focus has been on likely tax rises, the chancellor said the most recent figures from the fiscal watchdog had not changed her vow to election pledges not to increase rates on earnings tax, VAT or National Insurance.

She attributed an "unpredictable global environment" with increasing geopolitical and commercial tensions for the fiscal tax moves, probably to be directed on those "wealthiest."

Global Economic Tensions

Commenting on apprehensions about the United Kingdom's trade ties with the Asian nation she said: "Our security interests always take priority."

Recent declaration by China to tighten export controls on critical minerals and other materials that are crucial for high-technology production led US President Donald Trump to suggest an further 100% tariff on imports from the Asian country, raising the possibility of an all-out trade war between the two economic giants.

The US Treasury Secretary labeled the Chinese move "economic coercion" and "a international production power grab."

Questioned on accepting the American proposal to join its conflict with China, the Chancellor said she was "extremely troubled" by China's actions and urged the Chinese government "not to put up barriers and restrict access."

She said the move was "damaging for the global economy and generates additional headwinds."

"I believe there are areas where we need to confront Chinese policies, but there are also important chances to export to Chinese markets, including financial services and other sectors of the economy. We've got to get that balance appropriate."

The Treasury chief also affirmed she was working with international partners "regarding our own essential resources approach, so that we are more independent."

NHS Drug Costs and Investment

The Chancellor also acknowledged that the cost the National Health Service spends on medicines could increase as a consequence of ongoing discussions with the Trump administration and its drugs companies, in return for reduced taxes and capital.

A number of the world's largest drug companies have said lately that they are either pausing or scrapping projects in the United Kingdom, with several attributing the low prices they are obtaining.

Last month, the government science advisor said the cost the NHS pays for medicines would must rise to halt companies and pharmaceutical investment departing from the United Kingdom.

The Chancellor told the BBC: "It has been observed due to the pricing regime, that clinical trials, recent pharmaceuticals have not been available in the United Kingdom in the way that they are in other EU nations."

"The objective is to make sure that people getting treatment from the NHS are can obtain the top life-saving treatments in the globe. And so we are examining this situation, and... aiming to attract additional investment into the UK."